Aevi Genomic Medicine — Medgenics — Corporate Update (June 2016)
24 slides from Aevi Genomic Medicine's corporate update, Jun 6, 2016
Slide 1: Medgenics / Kyowa Hakko Kirin Collaboration for Severe Pediatric Onset IBD
Medgenics / Kyowa Hakko Kirin Collaboration for Severe Pediatric Onset Inflammatory Bowel Disease June 6, 2016
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results
Slide 3: Agenda
Agenda • Corporate Vision and Strategy • Executive summary of KHK Collaboration • Anti - LIGHT 1 Opportunity • Discovery of DcR3 role in IBD • Severe Pediatric Onset IBD • Rationale for anti - LIGHT • Development Strategy • Deal terms • Summary 1 LIGHT – also known as “ligand for herpesvirus entry m
Slide 4: Medgenics Vision
Medgenics Vision 4 Driven by our commitment to patients we strive to create the premier genomic medicine company by : • Developing first - to - market or best - in - class therapies that are transformative to patients suffering from life altering genetic diseases • Having unparalleled understanding
Slide 5: Medgenics/CHOP Collaboration
Medgenics/CHOP Collaboration 5 • Medgenics’ role: • Lead the translational process matching genetic discoveries with potential therapies • Acquire the rights to programs that have been abandoned • Ideal program: • C orrect MOA • E xcellent safety profile • F ailed in clinical trials due to poor effi
Slide 6: Benefits of Genomic Guided Drug Development
Benefits of Genomic Guided Drug Development Higher Value Medicines Improved response rates Smaller, faster, clinical trials Increased probability of regulatory success Targeted launch Potential label expansion in adjacent genetic diseases G enomic biomarkers improve overall program outcomes 6
Slide 7: Executive Summary
Executive Summary • First in Class Biologic from Kyowa Hakko Kirin (KHK) • Option to Phase 2 Ready Antibody – anti - LIGHT monoclonal antibody • Significant prior investment and advanced through Phase 1 • Strong Intellectual Property and Regulatory Exclusivity • Robust patent portfolio • 1 2 years o
Slide 8: Executive Summary (Continued)
Executive Summary (Continued) • Rapid and Capital Efficient Global Development Pathway • Minimal investment to Proof of Concept • H1 2017 • Single Pivotal Trial for Registration • World Class Partners • The Children’s Hospital of Philadelphia • Center for Applied Genomics – largest pediatric biobank
Slide 9: KHK: A Leading Biopharmaceutical Company in Japan
KHK: A Leading Biopharmaceutical Company in Japan • Established 1949 in Japan • ¥ 364B (~$3.0B) in consolidated net sales (2015) • Antibody - related cutting - edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company • Major monoclonal
Slide 10: CAG/CHOP Discovery: Genetic Link to Pediatric Onset IBD
CAG/CHOP Discovery: Genetic Link to Pediatric Onset IBD • Established importance of the DcR3 gene in pediatric IBD • Loss of function of DcR3 correlates with severity • Prevalence between 10 - 15% Nature Genetics VOLUME 40 | NUMBER 10 | OCTOBER 2008 10
Slide 11: IBD – Onset Prior to Age 17
Severe Pediatric Onset IBD – Onset Prior to age 18 1 Ruel , J. et al. (2013) IBD across the age spectrum — is it the same disease? Nat . Rev. Gastroenterol . Hepatol . doi:10.1038/nrgastro.2013.240 • Distinct condition with d ominant g enetic component 1 • Greater burden of illness • More aggressive
Slide 12: Pediatric vs. Adult Onset IBD: Disease Progression
Pediatric vs. Adult Onset IBD: Disease Progression Comparison of evolution of Crohn’s disease behavior between elderly - onset patients ( n = 367) and pediatric - onset patients ( n = 689) obtained from the EPIMAD registry 1 Ruel , J. et al. (2013) IBD across the age spectrum — is it the same diseas
Slide 13: Pediatric vs. Adult Onset IBD: Burden of Illness
Pediatric vs. Adult Onset IBD: Burden of Illness 1 Ruel , J. et al. (2013) IBD across the age spectrum — is it the same disease? Nat . Rev. Gastroenterol . Hepatol . doi:10.1038/nrgastro.2013.240 • Pediatric Onset Patients suffer from additional Risks/Complications, including 1 : • Malnutrition • Pe
Slide 14: IBD: Top Down Treatment Paradigm
Treatment Objectives : • Induce remission with anti - TNFα immediately so patients can develop normally • Avoid steroids and IMs • Manage utilization of anti - TNF alphas to extend time before resistance develops Severe Pediatric Onset IBD: “Top Down” Treatment Paradigm Opportunity: • 30% of patient
Slide 15: Anti-LIGHT Mab: High Quality Asset and Development History
Anti - LIGHT Mab: High Quality Asset and Development History • La Jolla Institute for Allergy and Immunology • Target discovered • Novel MOA in an established pathway • Kyowa Hakko Kirin • Human anti - LIGHT m A b • Robust patent protection & 12 years US regulatory exclusivity • Large pharma partner
Slide 16: Rationale for Anti-LIGHT Approach
Rationale for Anti - LIGHT Approach • DcR3 is strongly linked to Severe Pediatric Onset IBD 1 • Initial strategy to augment DcR3 – Very short half life – T oxicity reported w/ previous DcR3 analog • “Rational Search” based on biological pathway – LIGHT overexpressed in IBD – DcR3 LOF increases LIGHT
Slide 17: Mechanism of Action
Mechanism of Action Anti - LIGHT m Ab mimics the anti - inflammatory activity of DcR3 Activated T - cell Naïve T - cell Activated T - cell Naïve T - cell Activated T - cell Naïve T - cell T - cell co - stimulation LIGHT up - regulates immune response DcR3 down - regulates the immune response by bind
Slide 18: Human Biomarker Study Supports Role of LIGHT in IBD
Human Biomarker Study Supports Role of LIGHT in IBD Single center non - interventional biomarker study Data on File 0 0.5 1 1.5 2 2.5 3 Normal (n=26) Ulcerative Colitis (n=27) Crohn's Disease (n=28) LIGHT mRNA Fold Increase vs Normal 18
Slide 19: Development Strategy
Development Strategy • Focus on patients with Severe P ediatric O nset IBD with DcR3 mutations who have failed anti - TNFα m Ab therapy • Rapid POC • Clinical Trial Material available • Large cohort of patients identified at CHOP • Development program could be expanded to include: • All Pediatric IB
Slide 20: Rapid Pathway to Approval
Rapid Pathway to Approval Phase 2/3 mGluR+ ADHD, Adolescents (N = 90) Severe Pediatric Onset IBD POC Trial Signal Finding Trial design: - Single center (CHOP ) - N = up to 12 patients - Duration 8 – 12 weeks - Ascending dose Endpoints : - Endoscopic Evaluation , Pediatric Crohn’s Disease Activity In
Slide 21: IBD: Anti-LIGHT Opportunity (US Population)
Severe Pediatric Onset IBD: Anti - LIGHT Opportunity (US Population) Potential Upside: Pediatric anti - TNFα failures: 15,000 – 16,000 IBD Patients in US 1 Kappleman et al. (2007) Clin Gastro Hepat 2 Oliva - Hemker (2015) J Pedtr 3 Remicade Monograph 4 Altwegg - Vincent (2014) Mediators of Inflamm I
Slide 22: IBD Commercial Opportunity
Severe Pediatric Onset IBD Commercial Opportunity • With conservative p ricing e stimates and assuming a 15% prevalence rate of DcR3 LOF, the Severe Pediatric Onset opportunity in the US: • $300 - $400M • DcR3 LOF mutation who fail to respond to anti - TNFα • Significant upside potential • anti - TN
Slide 23: Deal Terms
Deal Terms • MDGN to: • Requalify KHK clinical supplies • C onduct s ignal f inding s tudy (~$2M) • Exercise option to license on positive data (low single - digit millions USD) • Following option exercise, KHK elects either: • Partnership • “Co - Development/Co - Commercialization ” – Parties share
Slide 24: Summary
Summary • First - in - Class Biologic from Kyowa Hakko Kirin • Initial Development in Severe Pediatric Onset IBD • Phase 2 Ready Antibody • Strong Regulatory Exclusivity and Robust Intellectual Property Portfolio • High Value Commercial Opportunity with Potential for Indication Expansion • World Cla